Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.67 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nelarabine SCHEMBL31326718 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL1818971 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL9937290 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL14031852 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13575801 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL2143756 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18321891 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13657986 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL20769831 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL29077509 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29613 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260146273-A1 | METHOD FOR ONE-POT BIOSYNTHESIS OF ARABINONUCLEOSIDE, AND COMPOSITION | ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | INCYTE CORP (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026101232-A1 | POLYMER COMPOUND FOR CELL SURFACE MODIFICATION FOR IMPROVING DRUG DELIVERY EFFICIENCY | 동국대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| WO-1998042352-A1 | METHOD FOR TREATING B-CELL TUMORS WITH ARA-G NUCLEOSIDE DERIVATIVES | GLAXO GROUP LTD. (GB) | 1998-10-01 | — | — | WO | claimed |
| US-5747472-A | ANTICARCINOGENIC AGENTS AND ANTITUMOR AGENTS | GLAXO WELLCOME INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0539479-B1 | HETEROCYCLIC COMPOUNDS | WELLCOME FOUND (GB) | 1997-04-16 | — | — | EP | claimed |
| EP-0294114-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-09-11 | — | — | EP | claimed |
| US-5492897-A | ANTITUMOR AGENTS, AUTOIMMUNE DISEASES | BURROUGHS WELLCOME CO. (141) (US) | 1996-02-20 | — | — | US | claimed |
| US-5424295-A | Useful in treatment of varicella-zoster virus infections | BURROUGHS WELLCOME CO. (US) | 1995-06-13 | — | — | US | claimed |